Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Shares Outstanding (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Shares Outstanding for 10 consecutive years, with $96.6 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 4.43% to $96.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $96.6 million through Dec 2025, up 4.43% year-over-year, with the annual reading at $96.6 million for FY2025, 4.43% up from the prior year.
  • Shares Outstanding for Q4 2025 was $96.6 million at Ultragenyx Pharmaceutical, roughly flat from $96.4 million in the prior quarter.
  • The five-year high for Shares Outstanding was $96.6 million in Q4 2025, with the low at $67.4 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $79.6 million, with a median of $71.8 million recorded in 2023.
  • The sharpest move saw Shares Outstanding increased 1.23% in 2022, then grew 28.92% in 2024.
  • Over 5 years, Shares Outstanding stood at $69.3 million in 2021, then increased by 1.23% to $70.2 million in 2022, then grew by 17.24% to $82.3 million in 2023, then increased by 12.39% to $92.5 million in 2024, then increased by 4.43% to $96.6 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $96.6 million, $96.4 million, and $96.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.